Historic Milestones

2011

April 2011

Founded by Cerberus Capital Management, the investment management firm with over $30 billion in assets under management.

December 2011

Acquired the U.S. marketing and distribution rights for Lanoxin®, Lanoxin® IV Parnate®, Zantac®, Fortaz® and Zinacef® from GlaxoSmithKline.

2012

January 2012

Initiated development of alternative dosage strengths of Lanoxin®.

October 2012

Entered into authorized generic agreement with Rising Pharmaceuticals for Parnate®.

2013

April 2013

Acquired the U.S. marketing and distribution rights for Kayexalate®, Nilandron®, Plaquenil®, Rilutek®, and Uroxatral® from Sanofi.

June 2013

Entered into authorized generic agreement with Rising Pharmaceuticals for Rilutek®.

October 2013

Received FDA approval for the alternative dosage strengths of Lanoxin®.

December 2013

Entered into authorized generic agreement with Par Pharmaceuticals for Lanoxin®.

2014

January 2014

Initiated funding of cardiology sales force for U.S. distribution partner to promote Lanoxin®.

February 2014

Acquired the U.S. marketing and distribution rights for DuToprol®.

October 2014

Acquired the U.S. marketing and distribution rights for Dibenzyline® and Dyrenium®.
Entered into authorized generic agreement with Prasco for several brands.

2015

January 2015

Acquired the U.S. marketing and distribution rights for Betapace® & Betapace AF®.

April 2015

Divested majority of product assets to Concordia Healthcare Corp in a deal valued at $1.2 billion.

May 2015

Acquired the U.S. marketing and distribution rights for Altoprev®.

2016

November 2016

Acquired the U.S. marketing and distribution rights for Sular®.

2017

April 2017

Acquired the U.S. marketing and distribution rights for Prilosec® Packets.

July 2017

Acquired the U.S. marketing and distribution rights for Alvesco®, Omnaris®, and Zetonna®.

2018

November 2018

Acquired global rights for Alvesco®, Omnaris®, and Zetonna®.

2020

February 2020

Funds managed by affiliates of Apollo Global Management acquired Covis Pharma from Cerberus.

November 2020

Covis Group completes acquisition of AMAG Pharmaceuticals along with the global rights for Makena® and Feraheme®.

Skip to content